The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood and was assessed by evaluating responses at different stages of infection. Undiluted sera from long-term nonprogressors (LTNP) had broad neutralizing antibodies against heterologous primary isolates and were more likely to neutralize the contemporaneous autologous isolate than were sera from short-term nonprogressors and progressors. In primary infection, envelope-specific IgG was detected before the initial decline in plasma viremia, but neutralizing antibodies developed more slowly. Here, neutralizing antibodies against strains SF-2 and MN were sometimes the first to be detected, but titers were low for at least 17 weeks from ...
The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunode...
The study of the evolution and specificities of neutralizing antibodies during the course of human i...
Objective: The native envelope gp160 trimer of HIV-1 is thought to shield vulnerable epitopes that c...
The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poor...
The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poor...
Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors...
Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors...
Neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates from 17 p...
Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a ...
<div><p>Background</p><p>Only a small fraction of HIV-1-infected patients develop broadly neutralizi...
A fraction of HIV-1 patients are able to generate broadly neutralizing antibodies (bNAbs) after 2 to...
BACKGROUND: Cytotoxic T lymphocytes have been shown to reduce viraemia during acute HIV-1 infection;...
A substantial proportion of human immunodeficiency virus type 1 (HIV-1)-infected individuals has cro...
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 va...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunode...
The study of the evolution and specificities of neutralizing antibodies during the course of human i...
Objective: The native envelope gp160 trimer of HIV-1 is thought to shield vulnerable epitopes that c...
The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poor...
The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is poor...
Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors...
Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors...
Neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates from 17 p...
Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a ...
<div><p>Background</p><p>Only a small fraction of HIV-1-infected patients develop broadly neutralizi...
A fraction of HIV-1 patients are able to generate broadly neutralizing antibodies (bNAbs) after 2 to...
BACKGROUND: Cytotoxic T lymphocytes have been shown to reduce viraemia during acute HIV-1 infection;...
A substantial proportion of human immunodeficiency virus type 1 (HIV-1)-infected individuals has cro...
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 va...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunode...
The study of the evolution and specificities of neutralizing antibodies during the course of human i...
Objective: The native envelope gp160 trimer of HIV-1 is thought to shield vulnerable epitopes that c...